A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
End of Life, Financing Senior Living – Consumer Education, Legislation
The Bipartisan Policy Center last week launched a new initiative to find a politically and fiscally viable way to improve the financing and delivery o...
Co-chairs of the Senate Alzheimer’s Task Force are urging fellow senators to sign on to their letter asking the Appropriations Committee to support re...
cheatsheet, Disabilities, End of Life, Health and Wellness, Health Care, Managed Risk
End of life planning can be one of the most difficult discussions to have for any family, but deciding about that care when you are healthy can help t...
Diane Doumas has been named interim Executive Director for the Center for Excellence in Assisted Living, a collaborative of 11 diverse national organi...
End of Life, Federal Agency Activity, Health and Wellness, Health Care
Think you’re too old to donate an organ? Think again! Any age is the right age to sign up to be an organ donor, says the Administration on Aging.
Facts and Figures, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education, Reports
A protein may hold the key to who gets Alzheimer’s, reports The New York Times, and it may have to do with stress.
cheatsheet, Clinical Quality and Quality Care Delivery, Engage, Health and Wellness, Risk Management
The intimacy and sexuality of older Americans is a topic of great importance to senior living communities as they work to ensure residents are treated...
cheatsheet, Facts and Figures, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education, Reports
There could be as many as 16 million Americans living with Alzheimer’s disease in 2050 at a cost of $1.2 trillion with women at a much higher risk of ...
While recent news reports trumpeted a new blood test designed to detect Alzheimer’s disease, the Boston Globe reports that the test is still years awa...
cheatsheet, End of Life, Facts and Figures, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education, Reports
Alzheimer’s disease is nearly as lethal as the two biggest killers in the United States, according to a new study. Approximately 500,000 people died i...